Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review
TLDR
Improving adherence in schizophrenia may have a considerable positive impact on patients and society by focusing on the identified multitude of factors driving nonadherence, including lack of insight, medication beliefs and substance abuse.Abstract:
Background:Nonadherence to medication is a recognized problem and may be the most challenging aspect of treatment.Methods:We performed a systematic review of factors that influence adherence and the consequences of nonadherence to the patient, healthcare system and society, in patients with schizophrenia. Particular attention was given to the effect of nonadherence on hospitalization rates, as a key driver of increased costs of care. A qualitative systematic literature review was conducted using a broad search strategy using disease and adherence terms. Due to the large number of abstracts identified, article selection was based on studies with larger sample sizes published after 2001. Thirty-seven full papers were included: 15 studies on drivers and 22 on consequences, of which 12 assessed the link between nonadherence and hospitalization.Results:Key drivers of nonadherence included lack of insight, medication beliefs and substance abuse. Key consequences of nonadherence included greater risk of relapse,...read more
Citations
More filters
Journal ArticleDOI
Attitudes toward and patterns of medication use among people with serious mental illness: There’s more than meets the eye
TL;DR: In this article , the subjective perceptions of factors that impact both attitudes toward and patterns of use of medication among individuals with serious mental illness (SMI) were explored, and three discrete sequential phases emerged, each characterized by different themes referring to attitudes toward medication and pattern of use.
Journal ArticleDOI
Continuity of care among patients newly initiated on second-generation oral or long-acting injectable antipsychotics during a schizophrenia-related inpatient stay.
Charmi Patel,Dominic Pilon,Laura Morrison,Christopher Holiday,Marie-Hélène Lafeuille,Patrick Lefebvre,Carmela Benson +6 more
TL;DR: In this article , the authors compared patients initiated on SGLAIs and OAAs in the United States and found that SGLAI patients were more likely to be adherent to the initiated antipsychotics and to have an outpatient visit, which may suggest improved continuity of care post-discharge relative to OAA patients.
Journal ArticleDOI
Association of Medication Nonadherence With Increased Risk of Violence to Others Among Patients With Schizophrenia.
TL;DR: Yang Li, MD, Hong Wen, BS; Chaoxinyu Xiong, MD; Chunying Lin, MD and Xianmei Yang, MD as mentioned in this paper have all been employed by IBM.
Journal ArticleDOI
Use of Long-Acting Injectable Antipsychotics in a Clinical Sample of Community-Dwelling Patients with Schizophrenia-Spectrum Disorders in Rural Greece
TL;DR: In this paper , the authors investigated the prescription patterns of LAIs in a clinical sample of patients with schizophrenia-spectrum disorders in rural Greece and found that most patients (72.4%) received antipsychotic monotherapy, and nearly 30% received an LAI formulation, mostly a second-generation LAI (20 of 26 patients, 76.9%), the treatment regimen comprised benzodiazepines in one third of the patients and antidepressants in one-quarter.
Journal ArticleDOI
Mortality and excess life-years lost in patients with schizophrenia under community care: a 5-year follow-up cohort study
TL;DR: Wang et al. as discussed by the authors evaluated the standardized mortality ratios (SMRs) of all-cause mortality and life-years lost (LYLs) in patients with schizophrenia under a community care program in China.
References
More filters
Journal ArticleDOI
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Alessandro Liberati,Douglas G. Altman,Jennifer Tetzlaff,Cynthia D. Mulrow,Peter C Gøtzsche,John P. A. Ioannidis,Mike Clarke,Mike Clarke,Philip J. Devereaux,Jos Kleijnen,David Moher +10 more
TL;DR: An Explanation and Elaboration of the PRISMA Statement is presented and updated guidelines for the reporting of systematic reviews and meta-analyses are presented.
Journal ArticleDOI
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
Alessandro Liberati,Douglas G. Altman,Jennifer Tetzlaff,Cynthia D. Mulrow,Peter C Gøtzsche,John P. A. Ioannidis,Mike Clarke,Mike Clarke,Philip J. Devereaux,Jos Kleijnen,David Moher +10 more
TL;DR: This Explanation and Elaboration document explains the meaning and rationale for each checklist item and includes an example of good reporting and, where possible, references to relevant empirical studies and methodological literature.
Journal ArticleDOI
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Jeffrey A. Lieberman,T. Scott Stroup,Joseph P. McEvoy,Joseph P. McEvoy,Marvin S. Swartz,Robert A. Rosenheck,Diana O. Perkins,Richard S.E. Keefe,Sonia M. Davis,C.E. Davis,Barry D. Lebowitz,Joanne B. Severe,John K. Hsiao +12 more
TL;DR: Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.
Journal ArticleDOI
The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.
Alan S. Bellack,Charles L. Bowden,Christopher R. Bowie,Matthew J. Byerly,William T. Carpenter,Laurel A. Copeland,Albana M Dassori,John M. Davis,Colin A. Depp,Esperanza Diaz,Lisa B. Dixon,John P. Docherty,Eric B. Elbogen,S. Nasser Ghaemi,Paul E. Keck,Samuel J. Keith,Martijn J. Kikkert,John Lauriello,Barry D. Lebotz,Stephen R. Marder,Joseph P. McEvoy,David J. Miklowitz,Alexander L. Miller,Paul A. Nakonezny,Henry A. Nasrallah,Michael W. Otto,Roy H. Perlis,Delbert G. Robinson,Gary S. Sachs,Martha Sajatovic,Nina R. Schooler,S. Charles Schulz,Jan Scoff,Jair C. Soares,Stephen M. Strakowski,Holly A. Swartz,Marcia Valenstein,Dawn I. Velligan,Peter J. Weiden,Emily M. Woltmann,John E. Zeber +40 more
TL;DR: Recommendations for addressing adherence problems to improve patient outcomes are developed, noting that multiple problems may be involved, requiring a combination of interventions.
Journal ArticleDOI
Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients With Schizophrenia
TL;DR: This study showed a direct correlation between estimated partial compliance and hospitalization risk among patients with schizophrenia across a continuum of compliance behavior.
Related Papers (5)
The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.
Alan S. Bellack,Charles L. Bowden,Christopher R. Bowie,Matthew J. Byerly,William T. Carpenter,Laurel A. Copeland,Albana M Dassori,John M. Davis,Colin A. Depp,Esperanza Diaz,Lisa B. Dixon,John P. Docherty,Eric B. Elbogen,S. Nasser Ghaemi,Paul E. Keck,Samuel J. Keith,Martijn J. Kikkert,John Lauriello,Barry D. Lebotz,Stephen R. Marder,Joseph P. McEvoy,David J. Miklowitz,Alexander L. Miller,Paul A. Nakonezny,Henry A. Nasrallah,Michael W. Otto,Roy H. Perlis,Delbert G. Robinson,Gary S. Sachs,Martha Sajatovic,Nina R. Schooler,S. Charles Schulz,Jan Scoff,Jair C. Soares,Stephen M. Strakowski,Holly A. Swartz,Marcia Valenstein,Dawn I. Velligan,Peter J. Weiden,Emily M. Woltmann,John E. Zeber +40 more